These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21122562)

  • 1. 5-aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study.
    Duricova D; Pedersen N; Elkjaer M; Jensen JK; Munkholm P
    J Crohns Colitis; 2010 Nov; 4(5):575-81. PubMed ID: 21122562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab dependency in children with Crohn's disease.
    Duricova D; Pedersen N; Lenicek M; Hradsky O; Bronsky J; Adamcova M; Elkjaer M; Andersen PS; Vitek L; Larsen K; Lukas M; Nevoral J; Wewer V; Munkholm P
    Aliment Pharmacol Ther; 2009 Apr; 29(7):792-9. PubMed ID: 19183163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
    Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
    Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort.
    Orlando A; Mocciaro F; Renna S; Scimeca D; Rispo A; Lia Scribano M; Testa A; Aratari A; Bossa F; Tambasco R; Angelucci E; Onali S; Cappello M; Fries W; D'Incà R; Martinato M; Castiglione F; Papi C; Annese V; Gionchetti P; Rizzello F; Vernia P; Biancone L; Kohn A; Cottone M
    J Crohns Colitis; 2014 Oct; 8(10):1217-21. PubMed ID: 24630485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011.
    Rungoe C; Langholz E; Andersson M; Basit S; Nielsen NM; Wohlfahrt J; Jess T
    Gut; 2014 Oct; 63(10):1607-16. PubMed ID: 24056767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
    Castillo-Regalado E; Ríos R; Aràjol C; Gely C; Márquez L; Calafat M; González-Muñoza C; Cañete F; Mesonero F; Guardiola J; Garcia-Planella E; Mañosa M; Domènech E
    Gastroenterol Hepatol; 2023 Mar; 46(3):164-170. PubMed ID: 36179946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS; Zlatanic J; Korelitz BI; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease.
    de Franchis R; Omodei P; Ranzi T; Brignola C; Rocca R; Prada A; Pera A; Vecchi M; Del Piano M; Ferrara A; Belloli C; Piodi L; Framarin L; Astegiano M; Riccioli FA; Meucci G
    Aliment Pharmacol Ther; 1997 Oct; 11(5):845-52. PubMed ID: 9354191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anastomotic configuration and mucosal 5-aminosalicyclic acid (5-ASA) concentrations in patients with Crohn's disease: a GISC study. Gruppo Italiano per lo Studio del Colon e del Retto.
    Frieri G; Pimpo MT; Palumbo G; Tonelli F; Annese V; Sturniolo GC; Andreoli A; Comberlato M; Corrao G; Caprilli R
    Am J Gastroenterol; 2000 Jun; 95(6):1486-90. PubMed ID: 10894584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
    Lochs H; Mayer M; Fleig WE; Mortensen PB; Bauer P; Genser D; Petritsch W; Raithel M; Hoffmann R; Gross V; Plauth M; Staun M; Nesje LB
    Gastroenterology; 2000 Feb; 118(2):264-73. PubMed ID: 10648454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.
    Schoepfer AM; Bortolotti M; Pittet V; Mottet C; Gonvers JJ; Reich O; Fournier N; Vader JP; Burnand B; Michetti P; Froehlich F
    Aliment Pharmacol Ther; 2014 Oct; 40(8):930-7. PubMed ID: 25146487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
    Elkjaer M
    Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
    Gross V; Andus T; Fischbach W; Weber A; Gierend M; Hartmann F; Schölmerich J
    Z Gastroenterol; 1995 Oct; 33(10):581-4. PubMed ID: 7502549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal effects of long-term treatment with 5-aminosalicylic acid.
    Patel H; Barr A; Jeejeebhoy KN
    Can J Gastroenterol; 2009 Mar; 23(3):170-6. PubMed ID: 19319380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
    Schreiber S; Howaldt S; Raedler A
    Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab dependency in a national cohort of children with Crohn's disease.
    Wewer V; Riis L; Vind I; Husby S; Munkholm P; Paerregaard A
    J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):40-5. PubMed ID: 16385252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.